Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

ADT Inc. (NYSE:ADT) is one of the best cheap stocks under $10 to buy now. Barclays analyst Manav Patnaik maintained a Hold ...

ADT Inc. (NYSE:ADT) is among the 13 Most Undervalued Stocks Under $20 to Buy. On November 4, the company reported financial ...

ADT entered the second half of 2025 with 4% total revenue growth, amid a slight dip in recurring monthly revenue (RMR), but ...

ADT reported higher Q3 earnings and cash flow driven by ADT+ adoption and operational discipline, even as attrition edged up ...

In a report released today, Manav Patnaik from Barclays maintained a Hold rating on Adt, with a price target of $9.00. The company’s shares closed yesterday at $8.08. Explore ETFs TipRanks' users love ...

ADT reported a 4% increase in total revenue, reaching $1.3 billion, and a significant 36% rise in adjusted free cash flow, including interest rate swaps, amounting to $709 million year-to-date. This ...

SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

Google’s home security partner, ADT, has a big discount available for anyone looking to start off a new security ...

BOCA RATON, Fla. — ADT Inc. has released its financial results for the third quarter of 2025. Financial highlights for the ...

Choosing the right home security system is something homeowners or renters likely want to get right the first time. But with so many options out there, it can seem difficult for potential customers to ...